KaydedilenlerDerginizi ekleyin

Dergiler / Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi / 2025 / Volume: 12 Issue: 3

Postmenopozal Kadınlarda Östrojen, Progesteron ve CA-125 Düzeyleri ile Endometrioid Endometrial Kanser Riski Arasındaki İlişki

The Relationship Between Estrogen, Progesterone and Serum CA-125 Levels and Endometrioid Endometrial Cancer Risk in Postmenopausal Women

Sema Mısır(SIVAS CUMHURIYET UNIVERSITY)0000-0002-5919-3295
Begüm Kurt(SIVAS CUMHURIYET UNIVERSITY)0000-0002-7166-3130
Serap Ozer Yaman(SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, TRABZON KANUNİ SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ)0000-0002-5089-0836
Ceylan Özsoy(SIVAS CUMHURIYET UNIVERSITY)0000-0001-6397-1291
Sayfa
—
Yayın Tarihi
2025-12-29
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Bulgularımız serum CA-125 düzeylerindeki yükselmenin ileri evre EEC'lerle pozitif ilişkili olduğu bulundu.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Bu çalışmada, postmenopozal kadınlarda serum östrojen (estradiol), progesteron ve serum kanser antijen 125 (CA-125) düzeyleri ile endometrioid endometrial kanser (EEC) riski arasındaki ilişki ve prognostik değerlerinin belirlenmesi amaçlandı.
📊
Temel Bulgular & Veri:Bu retrospektif çalışmaya, 50 yaş üstü postmenopozal hasta olmak üzere 160 kişi dahil edildi.
💡
Sonuç & Katkı:Bulgularımız serum CA-125 düzeylerindeki yükselmenin ileri evre EEC'lerle pozitif ilişkili olduğu bulundu.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:CA-125 Antigen · Endometrial Carcinoma · Estradiol

Özet

Bu çalışmada, postmenopozal kadınlarda serum östrojen (estradiol), progesteron ve serum kanser antijen 125 (CA-125) düzeyleri ile endometrioid endometrial kanser (EEC) riski arasındaki ilişki ve prognostik değerlerinin belirlenmesi amaçlandı. Bu retrospektif çalışmaya, 50 yaş üstü postmenopozal hasta olmak üzere 160 kişi dahil edildi. Histopatolojik olarak EEC’si doğrulanan hastalardan ameliyattan bir hafta önce belirlenen östrojen, progesteron ve CA-125 seviyeleri evrelere göre değerlendirildi ve korelasyon analizi evrelere göre Pearson testi kullanılarak yapıldı. Bulgularımız serum CA-125 düzeylerindeki yükselmenin ileri evre EEC'lerle pozitif ilişkili olduğu bulundu. Östrojen, progesteron seviyelerinin postmenopozal kadınlarda azaldığı ve postmenopozal progesteron ve östrojen seviyelerinin EEC riskiyle ters orantılı olduğu gözlendi. Progesteron ve östrojen arasında pozitif korelasyon gözlenirken, CA-125 seviyeleri ve progesteron, östrojen arasında negatif korelasyon gözlendi. Serum CA-125 düzeylerindeki yükselmenin ileri evre EEC'lerle pozitif, progesteron ve östrojen seviyelerinin ters orantılı olduğu belirlendi. Bu bulguları doğrulamak için daha geniş prospektif çalışmalara ihtiyaç vardır.

Abstract

This study aimed to investigate the relationship between serum levels of estrogen (estradiol), progesterone, and serum cancer antigen 125 (CA-125) and the risk of developing endometrioid endometrial cancer (EEC) in postmenopausal women, as well as to evaluate their prognostic significance. A total of 160 postmenopausal women over the age of 50 were included in this retrospective study. Among these, patients with histopathologically confirmed endometrioid endometrial cancer were selected. Serum estradiol, progesterone, and CA-125 levels, obtained within one week before surgery, were analyzed according to disease stage. Correlation analyses between hormone levels and cancer stages were conducted using Pearson's correlation test. The findings demonstrated a positive association between elevated serum CA-125 levels and advanced stages of EEC. Estradiol and progesterone levels were decreased in postmenopausal women, and lower serum levels of progesterone and estradiol were inversely associated with the risk of EEC. A positive correlation was observed between progesterone and estradiol levels, while negative correlations were identified between CA-125 and progesterone and estradiol levels. An increase in serum CA-125 levels was positively correlated with advanced stages of EEC, whereas decreased levels of progesterone and estradiol were inversely related to cancer risk. These findings suggest that further large-scale prospective studies are warranted to validate the prognostic value of these biomarkers.

🔖

Bu Makaleye Atıf Yap

Mısır, S., Kurt, B., Yaman, S. O., Özsoy, C. (2025). Postmenopozal Kadınlarda Östrojen, Progesteron ve CA-125 Düzeyleri ile Endometrioid Endometrial Kanser Riski Arasındaki İlişki. Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi, Volume: 12 Issue: 3. https://doi.org/10.47572/muskutd.1706330

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (28)

  1. Zamani N, Gilani MM, Mirmohammadkhani M, et al. The utility of CA-125 and HE4 in patients suffering from endometrial cancer. IJWHRS. 2020;8(1):95-100.
  2. Bassette E, Ducie JA. Endometrial Cancer in Reproductive-Aged Females: Etiology and Pathogenesis. Biomedicines. 2024;12(4):886.
  3. Gilani MM, Mehr SGD, Mousavi A, et al. The Importance of HE4 and CA 125 in Overall Survival and Recurrence-free Survival of Endometrial Cancer. EEC. 2022;89:89-9.
  4. Kurt B, Küçükyıldız İ, Yanık A. The predictive role of CA-125 value in early stage endometrioid endometrial cancer. Cumhuriyet Medical Journal. 2023;45(2):31-37.
  5. Forsse D, Tangen IL, Fasmer KE, et al. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Gynecol. Oncol. 2020;156(2): 400-406.
  6. Bukato K, Kostrzewa T, Gammazza AM, et al. Endogenous estrogen metabolites as oxidative stress mediators and endometrial cancer biomarkers. Cell Commun. Sıgnal. 2024; 22(1): 205.
  7. Purdie DM, Green AC. Epidemiology of endometrial cancer. Bes Pract. Res. Clin. Obstet. Gynaecol. 2001;15(3):341-354.
  8. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstetrics & Gynecology. 1993;81(2):265-271.
  9. Tian W, Teng F, Zhao J, et al. (2017). Estrogen and insulin synergistically promote type 1 endometrial cancer progression. Cancer Biol. Ther. 2017;18(12):1000-1010.
  10. Audet-Walsh E, Lepine J, Gregoire J, et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. JCEM. 2011;96(2):E330-E339.
  11. Brinton LA, Trabert B, Anderson GL, et al. Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2016;25(7):1081-1089.
  12. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. IJC. 2004;108(3):425-432.
  13. Potischman N, Hoover RN, Brinton LA, et al. Case—control study of endogenous steroid hormones and endometrial cancer. JNCI. 1996;88(16):1127-1135.
  14. Michels KA, Brinton LA, Wentzensen N, et al. Postmenopausal androgen metabolism and endometrial cancer risk in the women’s health initiative observational study. JNCI cancer spectrum. 2019;3(3):pkz029.
  15. Erturk A, Korkmaz E, Arslantas Z, et al. Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer. RAMB. 2024;70(5): e20231115.
  16. Liang C, Chen Y, Chen S, et al. KLRB1 is a novel prognostic biomarker in endometrial cancer and is associated with immune infiltration. Transl. Cancer Res. 2023;12(12):3641.
  17. Degez M, Caillon H, Chauviré-Drouard A, et al. Endometrial cancer: A systematic review of HE4, REM and REM-B. Clin. Chim. Acta. 2021;515:27-36.
  18. Chao A, Tang YH, Lai CH, et al. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol. Oncol. 2013;129(3):500-504.
  19. Granberg S, Wikland M, Friberg LG: Tumor marker CA125 level and ovarian volume at different cycle day periods and in postmenopause. Int. J Gynaecol. Obstet. 1990;33:149 -152,
  20. Zurawski Jr VR, Sjovall K, Schoenfeld DA, Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol. Oncol. 1990;36(3):299-305.
  21. Honma N, Hosoi T, Arai T, et al. Estrogen and cancers of the colorectum, breast, and lung in postmenopausal women. Pathol. Int., 2015;65(9): 451-459.
  22. Zhao H, Jiang Y, Liu Y, et al. Endogenous estrogen metabolites as biomarkers for Endometrial Cancer via a Novel Method of Liquid Chromatography-Mass Spectrometry with Hollow Fiber Liquid-Phase Microextraction. Horm Metab Res. 2014;47(02):158-164.
  23. Heidari F, Rabizadeh S, Mansournia MA, et al. Inflammatory, oxidative stress and anti-oxidative markers in patients with endometrial carcinoma and diabetes. Cytokine. 2019;120:186-190.
  24. Allen NE, Key TJ, Dossus L. Endogenous sex hormones and endometrial cancer risk in women in the European prospective Investigation into Cancer and Nutrition (EPIC). Endocr-Relat Cancer. 2008;15(2):485-497.
  25. Gompel A. Progesterone and endometrial cancer. Bes Pract. Res. Clin. Obstet. Gynaecol. 2020;69: 95-107.
  26. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod. Med. 2010;28(01):81-90.
  27. Wang SC, Wu CH, Fu HC, et al. Estrogen/Progesterone Receptor Expression and Cancer Antigen 125 Level as Preoperative Predictors to Estimate Lymph Node Metastasis in Endometrioid Endometrial Cancer. Int. J. Gynecol. Pathol. 2024;43(4):316-325.
  28. Trabert B, Geczik AM, Bauer DC. Association of endogenous pregnenolone, progesterone, and related metabolites with risk of endometrial and ovarian cancers in postmenopausal women: the B∼ FIT cohort. Cancer Epidemiol. Biomarkers Prev. 2021;30(11):2030-2037.